Arani Bose Sells 12,000 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) Director Arani Bose sold 12,000 shares of Penumbra stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $283.77, for a total transaction of $3,405,240.00. Following the transaction, the director now directly owns 314,819 shares of the company’s stock, valued at approximately $89,336,187.63. This represents a 3.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Penumbra Stock Down 2.3 %

Penumbra stock opened at $268.89 on Friday. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The firm has a market cap of $10.36 billion, a P/E ratio of 790.84, a P/E/G ratio of 2.83 and a beta of 0.51. The business has a fifty day moving average of $274.49 and a two-hundred day moving average of $242.13. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. On average, analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PEN. Citigroup boosted their target price on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. upped their price objective on Penumbra from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Oppenheimer started coverage on Penumbra in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 target price on the stock. Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Finally, Robert W. Baird raised their price target on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Penumbra has a consensus rating of “Moderate Buy” and a consensus target price of $294.47.

Institutional Trading of Penumbra

Institutional investors have recently modified their holdings of the company. True Wealth Design LLC acquired a new stake in Penumbra in the third quarter valued at approximately $26,000. UMB Bank n.a. boosted its position in shares of Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after purchasing an additional 70 shares in the last quarter. Hurley Capital LLC purchased a new position in Penumbra during the 4th quarter worth $56,000. Huntington National Bank increased its position in Penumbra by 138.7% during the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock valued at $63,000 after buying an additional 154 shares in the last quarter. Finally, Mather Group LLC. raised its stake in Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after buying an additional 208 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.